Biofrontera AG (B8FK) Fair Value & Analysis
Healthcare · DE · Market cap €14.7M
Fair value as of: Jun 26, 2026
Analysis
Biofrontera AG (B8FK) currently trades at €2.33, while our model-based Fair Value estimate is €1.35 — implying the stock looks roughly 42.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Biofrontera AG (B8FK) undervalued?
What is the fair value of B8FK?
What is the quality score of B8FK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.